drugset / Trial / NCT06951698

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

NCT06951698

Phase 3 Recruiting 274 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder

Timeline

Start
2025-06-11
Primary completion
2026-11-01
Completion
2026-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule
Subject Xanomeline Small molecule

Indications